Total Payments
$569,795
2024 Payments
$9,668
Companies
18
Transactions
101
Medicare Patients
49
Medicare Billing
$15,307
Payment Breakdown by Category
Research$444,910 (78.1%)
Consulting$112,965 (19.8%)
Travel$11,408 (2.0%)
Food & Beverage$511.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $444,910 | 55 | 78.1% |
| Consulting Fee | $112,965 | 24 | 19.8% |
| Travel and Lodging | $11,408 | 7 | 2.0% |
| Food and Beverage | $511.80 | 15 | 0.1% |
Payments by Type
Research
$444,910
55 transactions
General
$124,885
46 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacyclics LLC, An AbbVie Company | $198,950 | 24 | $0 (2019) |
| Hoffmann-La Roche Limited | $95,030 | 8 | $0 (2017) |
| Acerta Pharma LLC | $81,475 | 11 | $0 (2019) |
| F. Hoffmann-La Roche AG | $54,060 | 5 | $0 (2019) |
| Janssen Research & Development, LLC | $53,630 | 6 | $0 (2021) |
| Gilead Sciences, Inc. | $17,084 | 12 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $16,390 | 4 | $0 (2021) |
| Chugai Pharmaceutical Co., Ltd. | $14,629 | 4 | $0 (2019) |
| BeiGene, Ltd. | $10,250 | 6 | $0 (2024) |
| AstraZeneca UK Limited | $10,000 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,668 | 8 | BeiGene, Ltd. ($8,650) |
| 2023 | $450.00 | 1 | ABBVIE INC. ($450.00) |
| 2022 | $5,275 | 3 | Boehringer Ingelheim International GmbH ($2,925) |
| 2021 | $71,755 | 10 | Janssen Research & Development, LLC ($53,630) |
| 2020 | $12,320 | 4 | Novartis Pharmaceuticals Corporation ($10,350) |
| 2019 | $106,461 | 23 | Acerta Pharma LLC ($66,785) |
| 2018 | $200,953 | 23 | Pharmacyclics LLC, An AbbVie Company ($133,750) |
| 2017 | $162,913 | 29 | Hoffmann-La Roche Limited ($95,030) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $720.00 | General |
| Category: Oncology | ||||||
| 10/08/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: Oncology | ||||||
| 09/03/2024 | BeiGene, Ltd. | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| 09/03/2024 | BeiGene, Ltd. | — | Consulting Fee | Cash or cash equivalent | $360.00 | General |
| 06/11/2024 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $900.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 04/30/2024 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $100.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 01/04/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $17.69 | General |
| 11/24/2023 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 12/16/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,925.00 | General |
| 12/13/2022 | BeiGene, Ltd. | — | — | Cash or cash equivalent | $1,600.00 | Research |
| Study: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||||||
| 06/09/2022 | Novartis Pharma AG | KYMRIAH (Biological) | — | Cash or cash equivalent | $750.00 | Research |
| Study: CCTL019E2202 • Category: ONCOLOGY | ||||||
| 10/15/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $1,900.00 | Research |
| Study: A Study of PCI32765 Ibrutinib in Combination With Either Bendamustine and Rituximab or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Participants With Previously Treated Indolent Non Hodgkin Lymphoma | ||||||
| 09/16/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $29,960.00 | Research |
| Study: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||||||
| 08/06/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $20,300.00 | Research |
| Study: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||||||
| 07/02/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $805.00 | Research |
| Study: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||||||
| 05/03/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $595.00 | Research |
| Study: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||||||
| 04/15/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $70.00 | Research |
| Study: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | ||||||
| 03/01/2021 | BeiGene (Suzhou) Co., Ltd. | BRUKINSA (Drug) | — | Cash or cash equivalent | $450.00 | Research |
| Study: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) • Category: Oncology | ||||||
| 02/03/2021 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 01/18/2021 | BeiGene (Suzhou) Co., Ltd. | BRUKINSA (Drug) | — | Cash or cash equivalent | $7,175.00 | Research |
| Study: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) • Category: Oncology | ||||||
| 01/18/2021 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A PHASE II SINGLE ARM MULTICENTER OPEN LABEL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN ADULT PATIENTS WITH REFRACTORY OR RELAPSED FOLLICULAR LYMPHOMA • Category: ONCOLOGY | ||||||
| 07/30/2020 | BeiGene (Suzhou) Co., Ltd. | BRUKINSA (Drug) | — | Cash or cash equivalent | $630.00 | Research |
| Study: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL) • Category: ONCOLOGY | ||||||
| 07/27/2020 | BeiGene (Suzhou) Co., Ltd. | BRUKINSA (Drug) | — | Cash or cash equivalent | $90.00 | Research |
| Study: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL) • Category: ONCOLOGY | ||||||
| 05/28/2020 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | — | Cash or cash equivalent | $10,350.00 | Research |
| Study: A PHASE II SINGLE ARM MULTICENTER OPEN LABEL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN ADULT PATIENTS WITH REFRACTORY OR RELAPSED FOLLICULAR LYMPHOMA • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1130-CA | Pharmacyclics LLC, An AbbVie Company | $166,450 | 19 |
| PHASE 3 R R CLL WITH GDC0199 BR | Hoffmann-La Roche Limited | $95,030 | 8 |
| PH III GDC 199 GA101 VS GCHL IN CLL WITH COMORBIDITIES | F. Hoffmann-La Roche AG | $54,060 | 5 |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | Janssen Research & Development, LLC | $51,730 | 5 |
| PCYC-1112-CA | Pharmacyclics LLC, An AbbVie Company | $32,500 | 5 |
| A PHASE II SINGLE ARM MULTICENTER OPEN LABEL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN ADULT PATIENTS WITH REFRACTORY OR RELAPSED FOLLICULAR LYMPHOMA | Novartis Pharmaceuticals Corporation | $16,350 | 2 |
| A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | Acerta Pharma LLC | $12,495 | 1 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | BeiGene (Suzhou) Co., Ltd. | $7,625 | 2 |
| A Study of PCI32765 Ibrutinib in Combination With Either Bendamustine and Rituximab or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Participants With Previously Treated Indolent Non Hodgkin Lymphoma | Janssen Research & Development, LLC | $1,900 | 1 |
| CCTL019E2202 | Novartis Pharma AG | $1,750 | 3 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | BeiGene, Ltd. | $1,600 | 1 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL) | BeiGene (Suzhou) Co., Ltd. | $720.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 12 | 60 | $23,940 | $5,379 |
| 2020 | 2 | 37 | 138 | $41,432 | $9,928 |
Total Patients
49
Total Services
198
Medicare Billing
$15,307
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 60 | $23,940 | $5,379 | 22.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 26 | 98 | $25,732 | $6,239 | 24.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 40 | $15,700 | $3,689 | 23.5% |
About Dr. Anthony Letai, MD
Dr. Anthony Letai, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851368435.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Letai, MD has received a total of $569,795 in payments from pharmaceutical and medical device companies, with $9,668 received in 2024. These payments were reported across 101 transactions from 18 companies. The most common payment nature is "" ($444,910).
As a Medicare-enrolled provider, Letai has provided services to 49 Medicare beneficiaries, totaling 198 services with total Medicare billing of $15,307. Data is available for 2 years (2020–2021), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 03/02/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851368435
Products in Payments
- Ibrutinib (Drug) $198,950
- VENCLEXTA (Biological) $95,030
- CALQUENCE (Drug) $81,475
- GAZYVA (Biological) $54,060
- KYMRIAH (Biological) $18,100
- BRUKINSA (Drug) $15,795
- Non-Covered Product (Drug) $14,629
- ONCASPAR (Biological) $48.87
- ONCASPAR (Drug) $24.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Amir Fathi, M.d, M.D
Hematology & Oncology — Payments: $548,854
Hematology & Oncology $548,854